CRL Charles River Laboratories International, Inc.
Healthcare$156.73-2.23%ClosedMarket Cap: $7.55B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.67
P/S
1.92
EV/EBITDA
13.16
DCF Value
$132.93
FCF Yield
5.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
31.9%
Operating Margin
11.8%
Net Margin
-4.6%
ROE
-5.7%
ROA
-2.4%
ROIC
7.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $995.8M | 28.0% | $119.9M | $-14.8M | $— | — |
| Q4 null | $994.2M | 31.0% | $120.2M | $-276.6M | $— | — |
| FY null | $4.02B | 30.5% | $507.8M | $-144.3M | $— | — |
| Q3 null | $1.00B | 33.7% | $133.8M | $54.4M | $— | — |
| Q2 null | $1.03B | 34.6% | $100.1M | $52.3M | $— | — |
| Q1 null | $984.2M | 32.3% | $74.7M | $25.5M | $— | — |
| Q4 null | $1.00B | 28.4% | $-167.7M | $-215.7M | $— | — |
| FY null | $4.05B | 32.9% | $227.3M | $10.3M | $— | — |
| Q3 null | $1.01B | 34.6% | $117.4M | $68.7M | $— | — |
| Q2 null | $1.03B | 34.5% | $151.7M | $90.0M | $— | — |
| Q1 null | $1.01B | 34.1% | $126.0M | $67.3M | $— | — |
| Q4 2023 | $1.01B | 35.9% | $132.9M | $187.1M | $3.62 | — |